ARCHIVES

FDA Opponents Claim Abuses; Agency Doesn’t Attend Hearing

This article is from The Cancer Letter archive.

Vol. 21 No. 30 | July 28, 1995

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities: AACR Accepting Submissions for Two Dream Team Grants

September 19, 2014

Amgen Replaces “Bundling” Contract With Three Separate Contracts For Growth Factors.

September 5, 2008

Mail Mixup Delays July 23 Issue

August 6, 1976

BMS Agent Yervoy Received FDA Approval for Metastatic Melanoma

March 25, 2011

ASCO Recommends End of Life Discussions

January 28, 2011

Seer Places Survival Now at Least At 45 Percent, Could Be As High As 50 Percent For 1973-79 Patients

December 4, 1981